{"nctId":"NCT00368316","briefTitle":"Safety, Immunogenicity and Efficacy of Shigella Conjugate Vaccines in 1-4 Year Olds in Israel","startDateStruct":{"date":"2003-01"},"conditions":["Shigellosis"],"count":2799,"armGroups":[{"label":"S. sonnei conjugate vaccine","type":"EXPERIMENTAL","interventionNames":["Biological: Shigella conjugate vaccines"]},{"label":"S. flexneri 2a conjugate vaccine","type":"EXPERIMENTAL","interventionNames":["Biological: Shigella conjugate vaccines"]}],"interventions":[{"name":"Shigella conjugate vaccines","otherNames":["S. sonnei O-SP-rEPA conjugate.","S. flexneri 2a O-SP-rEPA conjugate."]}],"eligibilityModule":{"eligibilityCriteria":"* INCLUSION CRITERIA:\n\nVolunteers who are healthy 1-4 year old children whose parents/guardians have read the Information Sheet provided by the Principal Investigator and signed the consent form, and who will be available for follow up.\n\nEXCLUSION CRITERIA: Children with\n\n* chronic diseases receiving medication;\n* who have received systemic steroids during the month preceding Shigella vaccination;\n* who had severe side effects following vaccinations; and\n* those not available for follow up.","healthyVolunteers":false,"sex":"ALL","minimumAge":"1 Year","maximumAge":"4 Years","stdAges":["CHILD"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants With Adverse Events","description":"Number of participants with events per vaccine type and dose occuring in \\>=5% of participants","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"82","spread":null},{"groupId":"OG001","value":"61","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"79","spread":null},{"groupId":"OG001","value":"64","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"56","spread":null},{"groupId":"OG001","value":"72","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"36","spread":null},{"groupId":"OG001","value":"51","spread":null}]}]}]},{"type":"SECONDARY","title":"Geometric Mean Immunoglobulin G (IgG) Anti-Lipopolysaccharide (LPS) Levels","description":"Age-related homologous IgG anti-LPS levels","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.40","spread":null},{"groupId":"OG001","value":"18.98","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.71","spread":null},{"groupId":"OG001","value":"26.96","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.38","spread":null},{"groupId":"OG001","value":"43.86","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Efficacy","description":"Percent efficacy is defined as ((disease rate of controls minus disease rate of vaccinees) divided by disease rate of controls) times 100","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.8","spread":null},{"groupId":"OG001","value":"-8.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"35.5","spread":null},{"groupId":"OG001","value":"22.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"71.1","spread":null},{"groupId":"OG001","value":"-3.6","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":1434},"commonTop":["local pain, dose 1","local pain, dose 2","fever, dose 1","fever, dose 2"]}}}